Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 2
1993 4
1994 3
1995 6
1996 6
1997 4
1998 3
1999 9
2000 4
2001 4
2002 4
2003 2
2004 5
2005 7
2006 3
2007 5
2008 2
2009 7
2010 2
2011 4
2012 7
2013 4
2014 2
2015 4
2016 8
2017 2
2018 6
2019 3
2020 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Among authors: seiter kp. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Clinical Trial.
Myelodysplasia: new approaches.
Seiter K. Seiter K. Curr Treat Options Oncol. 2013 Jun;14(2):156-69. doi: 10.1007/s11864-013-0224-x. Curr Treat Options Oncol. 2013. PMID: 23436197
WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects.
Yokote K, Chanprasert S, Lee L, Eirich K, Takemoto M, Watanabe A, Koizumi N, Lessel D, Mori T, Hisama FM, Ladd PD, Angle B, Baris H, Cefle K, Palanduz S, Ozturk S, Chateau A, Deguchi K, Easwar TK, Federico A, Fox A, Grebe TA, Hay B, Nampoothiri S, Seiter K, Streeten E, Piña-Aguilar RE, Poke G, Poot M, Posmyk R, Martin GM, Kubisch C, Schindler D, Oshima J. Yokote K, et al. Among authors: seiter k. Hum Mutat. 2017 Jan;38(1):7-15. doi: 10.1002/humu.23128. Epub 2016 Oct 7. Hum Mutat. 2017. PMID: 27667302 Free PMC article. Review.
Toxicity of the topoisomerase II inhibitors.
Seiter K. Seiter K. Expert Opin Drug Saf. 2005 Mar;4(2):219-34. doi: 10.1517/14740338.4.2.219. Expert Opin Drug Saf. 2005. PMID: 15794715 Review.
Toxicity of the topoisomerase I inhibitors.
Seiter K. Seiter K. Expert Opin Drug Saf. 2005 Jan;4(1):45-53. doi: 10.1517/14740338.4.1.45. Expert Opin Drug Saf. 2005. PMID: 15709897 Review.
Osteochondral talar lesions and defects.
Seiter JL, Seiter KP Jr. Seiter JL, et al. Among authors: seiter kp jr. Clin Podiatr Med Surg. 2012 Oct;29(4):483-500. doi: 10.1016/j.cpm.2012.08.009. Clin Podiatr Med Surg. 2012. PMID: 23044058 Review.
Therapy for colorectal cancer.
Kemeny N, Seiter K. Kemeny N, et al. Among authors: seiter k. Curr Opin Oncol. 1991 Aug;3(4):745-52. Curr Opin Oncol. 1991. PMID: 1932233 Review.
119 results